No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BDX Becton Dickinson & Co
- 238.975
- +0.135+0.06%
Trading Jun 4 15:32 ET
69.07BMarket Cap52.99P/E (TTM)
239.750High237.190Low1.54MVolume238.610Open238.840Pre Close366.98MTurnover0.53%Turnover Ratio48.38P/E (Static)289.01MShares284.01952wk High2.69P/B68.90BFloat Cap224.00052wk Low3.72Dividend TTM288.33MShs Float284.019Historical High1.56%Div YieldTTM1.07%Amplitude13.066Historical Low238.510Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Citi Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Maintains Target Price $260
Citi analyst Joanne Wuensch maintains $Becton Dickinson & Co(BDX.US)$ with a hold rating, and maintains the target price at $260.According to TipRanks data, the analyst has a success rate of 61.2% and
Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis
By Denny Jacob Becton Dickinson stands to get a bigger strategic boost from its $4.2 billion acquisition of Edwards Lifesciences' critical care unit, according to some analysts, who otherwise view th
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Buy Rating
BofA Securities analyst Travis Steed maintains $Becton Dickinson & Co(BDX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 63.6% and a total average return of 6.4%
Express News | Becton, Dickinson and Company Files Prospectus Supplement for Senior Notes Offering; Size Not Disclosed - SEC Filing
Sell Ideas in Staples and Health Care - Oppenheimer
Express News | Becton, Dickinson and Company Shares Are Trading Higher After the Company Announced a Definitive Agreement to Acquire Edward's Critical Care Product Group
Comments
$Becton Dickinson & Co(BDX.US$ GAME OVER stock.
Despite a dip in earnings, Becton Dickinson's high P/E ratio persists due to anticipated robust future growth, outpacing the broader market. Investors' confidence in the company's future earnings is high, indicating the share price is unlikely to drop significantly soon.
$Becton Dickinson & Co(BDX.US$ BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
2
Dr. Silverman's extensive experience and zeal for innovation, evidence generation, clinical development, medical safety, and compliance is predicted to boost BD's innovation pipeline and foster improved, personalized care.
Market sentiment towards Becton, Dickinson and Company shows no major shift in the past year. However, the rise in total shareholder return hints at a growing positivity.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg